Department of Defense June 20, 2006 – Federal Register Recent Federal Regulation Documents
Results 1 - 4 of 4
Notice of Intent To Grant Exclusive Patent License; Soil and Topography, LLC
The Department of the Navy herby gives notice of its intent to grant to Soil and Topography Information, LLC., a revocable, nonassignable, exclusive license in the United States to practice the Government-Owned invention(s) described in U.S. Patent Number 5,316,950 entitled ``Method for quantitative calibration of in situ optical chemical measurements in soils using soil class and characteristics'', issue date May 31, 2002.
Notice of Intent To Grant Exclusive Patent License; SSC Development, LLC
The Department of the Navy hereby gives notice of its intent to grant to SSC Development, LLC, a revocable, nonassignable, exclusive license in the United States to practice the Government-owned invention(s) described in U.S. Patent No. 6,466,515 entitled, ``Power- Efficient Sonar System Employing a Waveform and Processing Method for Improved Range Resolution at High Doppler Sensitivity,'' issue date October 15, 2002.
TRICARE Program; Routine Care Not Directly Related to Study, Grant or Research Program
This proposed rule amends the exclusion of services and supplies provided as part of or under a research study, grant or research program to add coverage for routine patient care that would have been necessary in the absence of the study as well as care of complications that result from participation in the trial.
Civilian Health and Medical Program of the Uniformed Services (CHAMPUS)/TRICARE; Coverage of Phase II and Phase III Clinical Trials Sponsored by the National Institutes of Health National Cancer Institute
The final rule allows the Department of Defense to waive normal requirements so that covered beneficiaries can participate in Phase II and Phase III clinical trials sponsored or approved by the National Institutes of Health National Cancer Institute (NIH NCI). This waiver authority is expected to promote beneficiary access to promising new treatments and contribute to the development of such treatments.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
